Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
184
-
Total 13F shares, excl. options
-
15.1M
-
Shares change
-
+342K
-
Total reported value, excl. options
-
$1.75B
-
Value change
-
+$46.1M
-
Put/Call ratio
-
0.57
-
Number of buys
-
100
-
Number of sells
-
-72
-
Price
-
$115.90
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2018
210 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q2 2018.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 184 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.1M shares
of 27.8M outstanding shares and own 54.27% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.43M shares), VANGUARD GROUP INC (1.1M shares), FARALLON CAPITAL MANAGEMENT LLC (1.08M shares), RENAISSANCE TECHNOLOGIES LLC (879K shares), PRICE T ROWE ASSOCIATES INC /MD/ (855K shares), STATE STREET CORP (770K shares), DIMENSIONAL FUND ADVISORS LP (594K shares), FIRST MANHATTAN CO (569K shares), Krensavage Asset Management, LLC (519K shares), and Invesco Ltd. (509K shares).
This table shows the top 184 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.